Retatrutide acts on three metabolic receptors at once: GLP-1, GIP, and glucagon. This three-way activation is the key feature that sets it apart from earlier peptides in the same family. Lilly's TRIUMPH program is the registrational Phase 3 series in obesity, obstructive sleep apnea, and knee osteoarthritis. TRIUMPH-4 in knee osteoarthritis has read out, reporting about 28.7 percent weight reduction at 68 weeks alongside pain improvement. In the Phase 2 obesity trial, the highest dose group lost about 24 percent of body weight over 48 weeks, the largest reduction reported for any incretin-class research peptide so far. Trials report drops in triglycerides, LDL cholesterol, fasting glucose, blood pressure, and liver fat alongside the weight change, in line with broad metabolic activity. A Phase 2a trial in metabolic dysfunction-associated steatotic liver disease showed substantial drops in liver fat content, an effect tied to the glucagon arm of the triple mechanism. Meta-analyses position retatrutide ahead of semaglutide (single agonist) and tirzepatide (dual agonist) on weight reduction in head-to-head reviews of trial data. Obesity Type 2 diabetes Liver fat (MASLD) Metabolic markers Energy expenditure ## What is Retatrutide Retatrutide, also known by the code LY3437943, is a synthetic 39-amino-acid peptide developed by Eli Lilly. It belongs to the incretin family, the same family as semaglutide and tirzepatide, but it adds a third receptor target. Phase 2 trials in obesity and type 2 diabetes are complete and the Phase 3 TRIUMPH program is reading out, with TRIUMPH-4 in knee osteoarthritis reporting about 28.7 percent weight reduction at 68 weeks. We supply it as a lyophilized (freeze-dried) powder for laboratory research, with a batch-specific third-party certificate of analysis. ## How it works Retatrutide activates three metabolic receptors at the same time: - **GLP-1** receptor: slows stomach emptying and signals fullness - **GIP** receptor: improves how cells respond to insulin and shifts how lipids are processed - **Glucagon** receptor: raises energy expenditure and pushes the liver to burn fat Single-agonist peptides like semaglutide hit only the first receptor. Dual agonists like tirzepatide hit the first two. Adding the glucagon arm is what lets retatrutide drive the larger weight reduction and the liver-fat drop seen in trials. The three signals work together: appetite goes down, insulin response goes up, and the body burns more energy at rest. ## Often studied alongside Combined-peptide research often pairs retatrutide with growth-hormone-axis peptides such as tesamorelin, which is itself studied for visceral fat reduction, or with AOD-9604, a fragment of growth hormone investigated for fat metabolism. Both are available in research-grade form below. For reconstitution, the standard solvent in published protocols is bacteriostatic or sterile water. ## Documentation N Engl J Med, 2023, 48-week obesity trial showing about 24% weight reduction at top dose Lancet, 2023, Phase 2 trial in type 2 diabetes Nat Med, 2024, Phase 2a trial showing major liver fat reduction Diabetes Obes Metab, 2026, Phase 3 TRIUMPH program design Metabol Open, 2024, pooled analysis across randomized trials Lancet Diabetes Endocrinol, 2025, body composition substudy Biomolecules, 2025, mechanism and trial review This material is sold strictly for in-vitro research and laboratory use. Not intended for human or animal consumption, medical, cosmetic, or household applications. Suitable only for professional laboratory environments.

All Products

Categories

Tags

Availability

All Products

Categories

Tags

Availability